After a slow 2024, the biotech shell company Concentra Biosciences is back, offering to buy four biotechs in the past month ...

Discover why some biotechs fail but survive with cash on hand, and how players like Concentra are trying to unlock trapped ...

GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more than $600 million hit from its anti-TIGIT drug failure. | GSK’s ...

Concentra has a reputation for picking up biotechs that are down on their luck, and iTeos certainly fits the bill. The company’s main focus up until May was the anti-TIGIT antibody belrestotug ...

This follows the decision to discontinue the belrestotug program after it failed to meet key clinical endpoints.

In related developments, Wedbush downgraded iTeos stock from Outperform to Neutral but raised the price target from $10 to $12. Piper Sandler also adjusted its price target for iTeos, reducing it from ...

GSK was also developing a drug called belrestotug targeting TIGIT, another checkpoint, but abandoned it and an alliance with its originator, iTeos, in May.

GSK also reported on Wednesday a series of discontinuations in its pipeline. It is no longer investing in the anti-TIGIT antibody belrestotug, which it was developing alongside iTeos Therapeutics. The ...